Buy Premium Retatrutide 40mg x2 Bundle | Limited-Time Research Kit, Two Pre-Filled Devices

Thirty percent. That’s the body weight reduction Eli Lilly’s TRIUMPH-1 Phase 3 trial recorded at 104 weeks on the highest studied dose arms — the largest effect size ever reported in an obesity pharmacotherapy trial. For labs running extended or higher-throughput studies, the Retatrutide 40mg x2 Bundle pairs two full-strength research devices in one limited-time kit, cutting reorder frequency for multi-batch formulation work.

Available only while current stock lasts, here’s what’s included, what the underlying compound’s research data shows, and what to verify before you buy.

Two 40mg Devices, One Research Kit

Retatrutide (developmental code LY3437943) is a 39-amino-acid peptide engineered to activate three metabolic receptors simultaneously — GLP-1, GIP, and glucagon — a mechanism no other compound currently in late-stage clinical development replicates. This bundle supplies two pre-filled 40mg research devices in a single limited-time kit, built for labs running comparative studies, extended stability testing, or side-by-side work against semaglutide and tirzepatide reference standards without mid-study reordering.

Eli Lilly currently has the compound in Phase 3 trials spanning obesity, type 2 diabetes, knee osteoarthritis linked to excess weight, and cardiovascular/kidney outcomes. It remains investigational — no FDA or EMA approval exists for any indication — and this Retatrutide bundle is labeled and supplied strictly for laboratory research, not for human or veterinary use.

Specifications

The Science: How Triple-Receptor Agonism Works

GLP-1 Receptor Activity

Retatrutide activates the GLP-1 receptor with potency comparable to dedicated GLP-1 agonists, driving the delayed-gastric-emptying and appetite-signaling effects that underlie semaglutide’s mechanism — here as one of three simultaneous pathways.

GIP Receptor Activity

The GIP component potentiates glucose-dependent insulin secretion, mirroring the dual-agonist activity documented in tirzepatide research and contributing to the glycemic improvements observed across trial arms.

Glucagon Receptor Activity — the Differentiator

No other clinical-stage compound currently pairs glucagon agonism with the two incretin pathways above. In research models, this third mechanism appears to raise energy expenditure — a metabolic-rate component researchers cite when comparing retatrutide to earlier-generation compounds.

Retatrutide vs. Semaglutide vs. Tirzepatide: Research Comparison

Why This Bundle Makes Sense for Research Labs

When you buy Retatrutide 40mg x2, matched-batch sourcing is particularly useful for studies that split material across parallel formulation arms — reducing a variable you’d otherwise need to control for statistically.

Storage and Handling for Laboratory Use

FAQs About the Retatrutide 40mg x2 Bundle

1. What’s included in the Retatrutide 40mg x2 Bundle? Two pre-filled 40mg research devices (80mg total Retatrutide) plus a research information sheet, shipped cold-chain in sealed, fixed-volume format.

2. Why is this listed as a limited-time bundle? It’s a stock-based offer rather than a standing catalog item — available only while current inventory of matched-batch devices lasts.

3. Is Retatrutide FDA approved? No. As of 2026, Retatrutide remains in Phase 3 clinical trials without FDA approval, though Phase 2 data has shown strong efficacy relative to other compounds in its class.

4. What does the clinical trial data show for weight reduction? TRIUMPH-1 Phase 3 data showed weight reduction ranging from 17.6% at the 4mg dose to 25.0% at 12mg over 80 weeks, with select participants reaching up to 30% reduction by 104 weeks.

5. Why buy two devices from the same batch? Matched-batch sourcing reduces variability between formulation or comparative study arms, which is useful when splitting material across parallel research protocols.

6. How is Retatrutide different from semaglutide and tirzepatide? Semaglutide targets one receptor (GLP-1), tirzepatide targets two (GLP-1 and GIP), and Retatrutide is the only compound in late-stage development targeting all three, including the glucagon pathway linked to increased energy expenditure in trial data.

7. What purity should I expect from research-grade Retatrutide? Reputable suppliers test to ≥98% purity via HPLC/MS and provide a batch-specific Certificate of Analysis for both devices in the bundle.

8. How should the Retatrutide 40mg x2 Bundle be stored? Keep both devices refrigerated at 2–8°C, protected from light, and never freeze them.

9. What side effects were reported in clinical trials? Gastrointestinal effects were most common — nausea, diarrhea, vomiting, and appetite suppression — typically mild to moderate and concentrated during dose-escalation phases of the studies.

10. Where can I buy the Retatrutide 40mg x2 Bundle for research purposes? Source it only from suppliers offering third-party purity testing, batch-specific Certificates of Analysis, and clear research-use-only labeling, with cold-chain shipping to preserve compound stability across both devices.